Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Randox Launches Three New ELISA Kits for the Detection of Z Drugs

Published: Thursday, March 28, 2013
Last Updated: Thursday, March 28, 2013
Bookmark and Share
ELISA kits for the detection of Zopiclone, Zaleplon and Zolpidem in urine and blood specimens.

Randox Toxicology has launched three new ELISA testing kits for the detection of sedative drugs Zopiclone, Zaleplon and Zolpidem.

These drugs behave in a similar ways to benzodiazepines, a psychoactive drug which was traditionally used for the treatment of anxiety or insomnia.

The Z drugs are found in prescription medications; Lunesta, Ambien and Sonata, however they should only be used for a short time period as extended use can lead to tolerance.

The misuse of Z drugs is widespread as a result of both dependence and recreational use. Despite medical advice, many people continue to take these drugs for longer periods than their intended usage; leading to a potential over-dose and hazardous consequences.

Incidents of unusual or inappropriate behaviour have been linked to misuse of Z drugs, were the patient had no memory of their actions.

Some users have reported sleepwalking, sleep driving, binge eating, and performing other daily tasks while asleep. These side effects are troubling in a society were sleeping pills have boomed in popularity.

Randox Toxicology has developed three ELISA kits for the detection of Z drugs in urine and blood specimens.

The Zolpidem ELISA offers an unbeatable Limit of Detection (LOD) of 0.4ng/ml in urine and 0.52ng/ml in blood.

The Zopiclone and Zaleplon ELISA kits are the first immunoassays available for the rapid detection of these drugs. Prior to this, the only way to detect Zopiclone and Zaleplon was with timely chromatographic analysis.

Randox Toxicology also provides an automated ELISA plate reader, capable of reading 96 wells in 30 seconds.

In addition to the Z drug ELISA kits, Randox Toxicology provide a multiplex Biochip Array which targets Zolpidem, Zopiclone, Zaleplon and their metabolites simultaneously from a single, undivided specimen.

The advanced multiplex method consolidates ELISA tests onto a small 9x9mm biochip; enhancing the ability for toxicologists to quickly detect these sedatives.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!